Navigation Links
NIAID expands capability for influenza research and surveillance

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), today announced it is awarding $23 million per year for seven years to establish six Centers of Excellence for Influenza Research and Surveillance. Collectively, the centers will expand NIAID’s influenza surveillance program internationally and in the United States, and will bolster influenza research in key areas, including understanding how the virus causes disease and how the human immune system responds to infection with the virus. The goal of the newly created centers is to provide the federal government with important information to inform public health strategies for controlling and lessening the impact of seasonal influenza as well as an influenza pandemic.

“The threat of an influenza pandemic is a major source of concern for the public health community,?says NIAID Director Anthony S. Fauci, M.D. “The new NIAID Centers of Excellence for Influenza Research and Surveillance will help expand the federal government’s existing international and domestic influenza surveillance efforts, further our understanding of influenza viruses, and generate the information and tools necessary to better prepare and respond to a pandemic situation.?

The new awards build upon an ongoing program led by St. Jude Children’s Research Hospital in Memphis, TN, initiated by NIAID after the 1997 Hong Kong outbreak of highly pathogenic avian influenza in humans. Under this program, researchers conducted surveillance of influenza viruses in aquatic birds and live bird markets in Hong Kong, which helped shed light on the natural history of flu viruses. Further, scientists conducted training courses in animal influenza surveillance, developed diagnostic tools to detect animal flu viruses, and generated viruses suitable for use in developing human influenza vaccines.

NIAID is expanding the surveillance and research program to now include six Centers of Excellence for Influenza Research and Surveillance. Their work will include determining the prevalence of avian influenza in animals that routinely come into close contact with people; understanding how flu viruses evolve, adapt and transmit infection; and identifying immunological factors that can determine whether a flu virus causes only mild illness or death. Additionally, some centers will monitor for international and domestic cases of animal and human influenza to rapidly detect and characterize viruses that may have pandemic potential and to create vaccine candidates targeted to those viruses. Ultimately, these studies will lay the groundwork for developing new and improved control measures for emerging and reemerging flu viruses.

Summaries of the six NIAID Centers of Excellence for Influenza Research and Surveillance awards are provided below.

St. Jude Children’s Research Hospital, Memphis (principal investigator—Dr. Robert Webster) Research activities will involve evaluating antiviral drug regimens and factors that drive drug resistance; identifying viral markers that may indicate how a virus becomes deadly, adapts and transmits infection; uncovering immune system mechanisms that protect against the H5N1 avian flu virus; and identifying the factors that make animals and people susceptible to flu virus infection. In addition, St. Jude will expand its animal surveillance to more than a dozen countries and multiple U.S. states. St. Jude also will monitor pediatric populations for flu activity and maintain a surveillance component to monitor for evidence of the reemergence of the severe acute respiratory syndrome (SARS). Additionally, the researchers will explore strategies for controlling influenza outbreaks in agricultural settings.

University of California at Los Angeles (principal investigator—Dr. Scott Layne) UCLA investigators will monitor animal influenza internationally and in the states of Alaska, Washington and Califor nia. They also will maintain a high-throughput laboratory network capable of providing real-time information about circulating influenza virus strains and antiviral drug resistance—information that will be most critical during the early stages of an influenza pandemic.

University of Minnesota, Minneapolis (principal investigator—Dr. Marguerite Pappaiaonou) These researchers will conduct international and domestic animal flu surveillance covering all major domestic flight paths of migratory birds. This center also will carry out a human influenza surveillance study in Thailand and will monitor U.S. agricultural workers who work with swine.

Emory University, Atlanta (principal investigator—Dr. Richard Compans) This center will conduct studies to determine how influenza viruses adapt to new hosts and are transmitted between different hosts, and analyze human immune responses to influenza vaccination and infection. The researchers will examine how human genes might be silenced to decrease or eliminate flu infections; identify new targets for antiviral medicines; and evaluate flu transmission between patients and physicians in the hospital emergency room setting. Emory will also offer a training program for postdoctoral fellows and veterinarians interested in influenza and other research performed in a biosafety level 3 laboratory.

Mount Sinai School of Medicine, New York City (principal investigator—Dr. Adolfo Garcia-Sastre) These researchers will conduct molecular studies to identify influenza virus genes associated with the development of disease, the adaptability of flu viruses in birds and mammals, and the transmission of flu viruses between different hosts.

University of Rochester, Rochester, NY (principal investigator—Dr. John Treanor) Dr. Treanor and his colleagues will establish a human surveillance system that will monitor selected communities in New York for seasonal flu virus infections, and will study the effecti veness of annual immunization programs using inactivated or weakened (live, attenuated) flu virus vaccines. The Rochester center also will perform clinical immunological studies to better define human immune responses to influenza vaccination and infection. Additionally, the center will study how flu viruses adapt to new species of animals.


'"/>

Source:NIH/National Institute of Allergy and Infectious Diseases


Related biology news :

1. NIAID Initiates Trial of Experimental Avian Flu Vaccine
2. NIAID begins clinical trial of West Nile virus vaccine
3. New NIAID grants strengthen national biodefense and emerging infectious diseases research network
4. NIAID researchers show how promising TB drug works
5. NIAID DNA vaccine for H5N1 avian influenza enters human trial
6. International HapMap consortium expands mapping effort
7. Gene expands malarias invasion options
8. MWG Biotech expands siMAX?siRNA portfolio with new scales, lengths and design tools
9. NHGRI expands effort to revolutionize sequencing technologies
10. New book expands biological classifications to account for alien life
11. New study expands understanding of the role of RNA editing in gene control
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/2/2016)... , Feb. 2, 2016 This ... the bioinformatic market by reviewing the recent advances ... tools that drive the field forward. Includes forecast ... Identify the challenges and opportunities that exist ... and software solution developers, as well as IT ...
(Date:2/2/2016)... MOUNTAIN VIEW, Calif. , Feb. 2, 2016 ... diabetic retinopathy market, Frost & Sullivan recognizes US-based ... North America Frost & Sullivan Award for New ... technology provider in North America ... standard in the rapidly growing diabetic retinopathy market. ...
(Date:1/28/2016)... -- Synaptics (NASDAQ: SYNA ), a leading developer of human ... December 31, 2015. --> --> ... 2 percent compared to the comparable quarter last year to $470.5 ... $35.0 million, or $0.93 per diluted share. ... quarter of fiscal 2016 grew 9 percent over the prior year ...
Breaking Biology News(10 mins):
(Date:2/11/2016)... International, a not-for-profit organization focused on the ethics and governance ... to patients around the world, today announced that the editors ... the Good Pharma Scorecard an ,Editors, Pick, ... of BMJ Open ,s ,Most Popular Articles, which includes ... read. Ed Sucksmith , assistant editor of ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... focused on the development and manufacture of biopharmaceuticals and therapeutics, announces an ... the 2016 BioProcess International Awards – Recognizing Excellence in the People, Organizations ...
(Date:2/11/2016)... 2016   BioInformant announces the February 2016 ... Products, Opportunities, Tools, and Technologies – Market Size, Segments, ... The first and only ... industry, BioInformant has more than a decade of historical ... by stem cell type. This powerful 175 page global ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... of its new stem cell treatment clinic in Quito, Ecuador. The new facility ... and trauma applications to patients from around the world. , The new ...
Breaking Biology Technology: